Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96F25
UPID:
ALG14_HUMAN
Alternative names:
-
Alternative UPACC:
Q96F25; A8K030
Background:
The UDP-N-acetylglucosamine transferase subunit ALG14 homolog plays a crucial role in protein N-glycosylation, a fundamental process for protein folding and stability. It is part of the dolichol-linked oligosaccharide pathway, anchoring the catalytic subunit ALG13 to the ER, which is essential for the synthesis of glycoproteins.
Therapeutic significance:
ALG14's involvement in congenital myasthenic syndrome, intellectual developmental disorders with epilepsy, and progressive cerebral atrophy highlights its potential as a target for therapeutic intervention. Understanding the role of UDP-N-acetylglucosamine transferase subunit ALG14 homolog could open doors to potential therapeutic strategies.